Michael Pearson

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were lower by more than 6 percent Thursday and now down nearly 30 percent over the past three months. Valeant announced on Wednesday it has responded to government inquiries into its drug pricing practices. Sumant Kulkami of Bank of...

Canadian pharmaceutical behemoth Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Thursday that it would be acquiring Sprout Pharmaceuticals Inc., the maker of female libido drug Addyi for $1 billion. On Tuesday, Addyi received FDA's approval, becoming the first female libido drug...

U.S. markets were little changed to start the week as equities took a back seat following a bearish oil call at Goldman Sachs. Analysts at Goldman Sachs placed a $75-per-barrel target on crude oil, noting that supply will outpace demand in the coming year. The National Association of Realtors...

U.S. stocks rebounded from a two-day decline despite the fact that the U.S. economy contracted 2.9 percent in the first quarter. Investors showed little concern to the GDP figure which was negatively impacted by weather. The second quarter GDP figure, when released, may prove to be more market...